Partners and network - Protein Profiling | Sciomics

Partners

 

Organoid models

 

 

OrganoTherapeutics

OrganoTherapeutics develops advanced human brain organoid models to study neurodegenerative diseases.

In collaborative studies we performed in-depth proteomic profiling of Parkinson’s Disease using patient-derived striatum and NESC-derived organoids. This partnership enables deeper molecular insights, supporting target identification and accelerating the development of Precision Medicine approaches for neurological disorders.

 

 

Animal models

 

 

Phenos GmbH

Contract research organisation offering services and research expertise to pharmaceutical companies and academia. PHENOS core expertise is the physiological and pathological analysis of mice and rat models. Using its long lasting experience in in-vivo models, Phenos provides its sophisticated expertise in three major areas:

  • Phenotypical analysis of genetic altered mice (e.g. knock-out animals)
  • Preclinical in-vivo evaluation of new drug compounds
  • Identification of new therapeutic strategies of approved drugs
  • Animal models for the study of kidney disease

 

 

Antibody Specificity Assessment

 
 

Cambridge Protein Arrays Ltd.

Cambridge Protein arrays is a CRO offering analysis services based on complex human protein arrays. While the antibody arrays of Sciomics can be used to profile the content of proteins in a sample, recombinant protein arrays are especially useful for the interpretation of binding parameters of antibodies or auto-antibodies to a human proteins. Such arrays provide ultimate insights in the specificity of an antibody and information on eventual cross-binding events.
   

 

PEPperPRINT GmbH

Pepperprint offers standard and customized peptide microarrays with their proprietary LASER peptide printing technology which combines high spot densities with content flexibility, production speed and quality in a uniquely cost-effective manner. 
 

 

Recombinant antibodies

 

  
   

YUMAB GmbH

YUMAB provides tailored solutions for human antibody development and antibody engineering problems. YUMAB provides rapid, large-scale discovery and optimization of human monoclonal antibodies, custom libraries, antibody engineering (e.g., humanization, affinity maturation, various antibody product formats), and custom-made antibodies to difficult antigen targets. YUMAB offers fee-for-service solutions, and attractive and flexible licensing options for diagnostics and therapeutics. 

 

Instrumentation

 
 

DITABIS AG

DITABIS entwickelt und fertigt auf der Basis von OEM-Partnerschaften Medizingeräte, Laborgeräte oder Imagingsysteme für Anwendungen in den Bereichen Health Care, Life Science und In-Vitro-Diagnostik.

 

 

 

 

Research projects

 

 

MCDS-Therapy (@MCDS-Therapy)

A Horizon 2020 funded 5-year clinical trial for the repurposing of carbamazepine for the treatment of metaphyseal chondrodysplasia, type Schmid.

> Read our press release
     

 

 

 

Networks

 

 

BIO Deutschland

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.
   

DECHEMA

DECHEMA is the expert network for chemical engineering and biotechnology in Germany. As a non-profit professional society we represent these fields in science, industry, politics and the general public. DECHEMA promotes scientific and technical exchange among experts from different disciplines, organisations and generations. We consolidate the know-how of over 5,800 individual and sustaining members.
 

BioRN

Over the past few years the Rhine-Neckar biotech region has developed into one of Germany’s strongest biotechnology clusters. The cluster is located within a radius of 30 km around the cities of Heidelberg, Mannheim, Darmstadt and Ludwigshafen. It is the most prominent and concentrated biotech cluster in Germany in the fields of personalized medicine and cancer research.
 

Technologiepark Heidelberg

Heidelberg Technology Park is a science park where major research institutes and global corporations work side by side. The synergies are manifold so that what emerges is a science-based society in which science finds scope for experimentation in industry and scientific research gains new perspectives as a result of international cooperation.
 

BioLAGO e.V.

BioLAGO is the cross-border health network for life sciences in the four-country-region of Lake Constance (Germany, Switzerland, Austria and Liechtenstein). The network links industry with science for innovations; it promotes knowledge transfer and the foundation of new firms.
 

Network Lab-on-a-Chip Technologies

Lab-on-a-Chip approaches (short: LoaC) are the combination and integration of several analytical steps of classical and new laboratory analysis on a glass, silicium or plastic chip. The goal is to achiev a high degree of automation as well as the parallelization of many analytical steps (keyword " High Content Screening").

The network focuses on innovative products, production processes and services primarily in the fields of

  • Point-of-care diagnostics systems / Biomarker development
  • Replacement of animal experiments by "organ-on-a-chip" approaches
  • cell analysis / microbiology
  • chip manufacturing

 

News

Article | Stromal Chemokine Rewiring in B Cell Lymphoma

| March 2026 | Inflammatory reprogramming of stromal chemokine networks drives tissue disorganisation and disease progression in nodal B cell lymphoma. Sciomics supported the study with secretome profiling of human iFRC supernatant samples using the scioCD affinity proteomics platform.

Czernilofsky et al., Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma. Nature Cancer. 2026;7:538-552.  
Article | Fimepinostat Targets HDAC2 to Suppress Schwannoma Growth

| March 2026 | The HDAC inhibitor fimepinostat effectively induces apoptosis and suppresses tumor cell proliferation, highlighting its potential as a therapeutic strategy for schwannoma.
Sciomics supported the study with proteomic profiling and post-translational modification analysis of human cell samples.

Nagel et al., Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636  
Article | Parkinson’s Striatum Organoids Show Increased Inflammation Hallmarks

| February 2026 | Patient-derived striatum organoids carrying the LRRK2-G2019S mutation reveal early Parkinson’s Disease features, including neuroinflammation and altered signalling. Sciomics supported the study by analysing patient-derived striatum organoids using the scioDiscover proteomic microarray.

Barmpa et al., Parkinson’s Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation. Mov Disord. (2026), published online February 11, 2026  
Article | Fos-induced Osteosarcoma Links Cachexia-like Wasting to FGF21

| February 2026 | Fos-driven osteosarcoma induces systemic metabolic alterations and identified FGF21 as a key mediator and promising biomarker of cancer-associated cachexia. Sciomics supported the study by analysing murine serum samples using the scioDiscover proteomic microarray.

Luther et al., Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels. Cancer Metab. (2026)  
Article | Transpulmonary Pressure-Guided PEEP Improves Lung Protection

| October 2025 | In a porcine lung injury model, transpulmonary pressure–guided PEEP titration improved mechanics and reduced tidal stress. Sciomics supported the study by analysing cytokine, chemokine, and surface marker expression levels in plasma samples using the scioCD Precision Proteomics platform.

Mutschler et al., Optimizing Positive End-Expiratory Pressure in Asymmetric Acute Lung Injury in a Porcine Model: The Role of Transpulmonary Pressure. Int. J. Mol. Sci. 2025, 26, 9985  

Meet us

BIO 2026—San Diego (June 22-25, 2026)

We are excited to be part of BIO International Convention (June 22-25 in San Diego). Meet our CEO Dr. Christoph Schröder at the German Pavilion.
Swiss Biotech Day 2026—Basel (May 04-05, 2026)

Meet Dr. Ronny Schmidt, our VP Contract Research on-site at Swiss Biotech Day (May 04-05 in Basel).
bioRN Lounge (every last Tuesday of the month)

Want to meet in person? Talk to us at the bioRN Lounge, the regional monthly networking event in Heidelberg taking place every last Tuesday of the month.

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

BACK_TO_TOP